Introduction {#sec0001}
============

Cepharanthine (CEP, [Fig. 1](#fig0001){ref-type="fig"} ) is a natural product and an approved drug used for more than 70 years in Japan to treat a variety of acute and chronic diseases, such as venomous snakebites, alopecia, malaria and a few other pathologies, without major side effects. A variety of biological effects responsible for the clinical activities have been attributed to CEP. In this review, I shall try to summarize the recent findings accumulated with this compound and discuss its therapeutic potential. The history of the drug discovery and development is also highlighted here. The clinical efficacy of CEP has been discussed in previous reviews ([@bib0026], [@bib0098]) but an update of its properties and applications is useful.Fig. 1Chemical structure and conformation of cepharanthine (C~37~H~38~N~2~O~6~).Fig 1

Origin, discovery and development of CEP {#sec0002}
========================================

CEP is isolated from plants of the genus *Stephania* which is one of the biggest genera belonging to moonseed family Menispermaceae. The name *Stephania* may come from the Greek stefanos, a crown or garland. This alkaloid is found in several *Stephania* species, principally *S. rotunda* Lour and *S. cephalantha* Hayata (known as « Tamasaki-tsuzurafuji » in Japanese; « jin qian diao wu gui » \[金 线 吊 乌 龟\] in Chinese ([@bib0040]); « Bình vôi hoa đầu » in Vietnamese), but also in *S. sasakii* Hayata (known as « Koto-tsuzurafuji » in Japanese), *S. suberosa* Forman, *S. epigaea* ([@bib0073]) and *S. japonica* ([Fig. 2](#fig0002){ref-type="fig"} ). *Stephania rotunda* is a creeper commonly found in the mountainous areas of Cambodia and throughout Southeast Asia (Cambodia, Vietnam, Laos, and India). The plant *Stephania cephalantha* is native to China and Taiwan, where it was used as an indigenous medicine or Chinese herbal medicine. A botanist of Taipei Imperial University, Bunzo Hayata, reported the use of the plant for the first time in 1914. The correct botanical name is *S. cephalantha* although the literature principally mentions the plant as *S. cepharantha*. The vast majority of publications refer to *S. cepharantha* and rarely *S. cephalantha*. It is a very common misspelling. *Stephania* are wild plants, rich in alkaloids, commonly used in traditional food and medicine in Asia for the treatment of fevers.Fig. 2(a) *Stephania japonica* JB Koishikawa, photo of the plant leaves (Japan, 2018). (b) The caudex of *Stephania rotunda* (Pierre Fabre Botanical Institute, Cambounet-sur-Sor, France). (c and d) *Stephania cephalantha* Hayata (China), from the Paris Herbarium, at the National Museum of Natural History, Paris, France (<http://coldb.mnhn.fr/catalognumber/mnhn/p/p02467444> and p02384134).Fig 2

More than 600 alkaloids have been isolated from the genus *Stephania* and about 40 different alkaloids were characterized from *S. cephalantha* extracts ([@bib0103]). The chemical composition of extracts varies from one region to another and according to the harvest period. CEP is generally more abundant in the tubers of the plant than the roots and is also found in the leaves and seeds of the plant, which is cultivated in Japan ([@bib0017]). It is important to mention that in certain countries, in France in particular, the use of extracts of *S. cepharantha* is forbidden due to the risk of potential substitution with other toxic plants having similar Chinese names (notably *Aristolochia fanghi*, containing aristolochic acids which are nephrotoxic compounds) ([@bib0103]). The principle of pharmacovigilance applied to herbal medicinal products (or phytovigilance) is now well taken in account by the international health agencies ([@bib0061]). CEP has also been detected in *Radix Tinosporae*, an herb used in traditional Chinese medicine for the treatment of various inflammatory diseases ([@bib0129], [@bib0069]). This is perhaps not entirely surprising because *Tinosporae Radix* is the dried root tuber of *Tinospora sagittata* (Oliv.) Gagnep., which also belongs to the family Menispermaceae.

The pharmacist Heisaburo Kondo purified the active ingredient in 1934 from *S. cepharantha* and named it cepharanthine after its binomial nomenclature ([Fig. 3](#fig0003){ref-type="fig"} ). In 1938, a US patent application by Kondo and collaborators referred to the preparation of alkaloids from *S. cepharantha* and the isolation of CEP itself. From a chemical point of view, CEP is biscoclaurine alkaloid, also known as 12-O-methyl cepharanoline and it belongs to a large family of structurally close bisbenzylisoquinoline (BBIQ) cyclic alkaloids which includes fangchinoline, tetandrine, hernandezine, berbamine, daphnoline, cycleanine ([Fig. 4](#fig0004){ref-type="fig"} ), and many other BBIQ cyclic and non-cyclic, cited in [Table 1](#tbl0001){ref-type="table"} (note the unlimited originality of their names). These compounds bear two coclaurine units joined head-to-tail or head-to-head, but the chemical diversity is huge and about 500 BBIQs are known in this class ([@bib0008], [@bib0127]). In CEP, the two BIQ units are joined head-to-head and the alkaloid has an elliptic macrocyclic structure ([Fig. 1](#fig0001){ref-type="fig"}).Fig. 3History of CEP discovery and development. Eighty years of evolution of CEP, to mention its main clinical applications and biochemical properties.Fig 3Fig. 4Structure of six bisbenzylisoquinoline (BBIQ) derivatives.Fig 4Table 1Bisbenzylisoquinoline (BBIQ) alkaloids.Table 1Main BBIQsPlantsCitations[a](#tb1fn1){ref-type="table-fn"}ReferencesTetrandrine*Stephania tetrandra*910[@bib0068]Cepharanthine*Stephania cephalantha, S. rotunda*331Berbamine*Berberis amurensis, B. vulgaris, B. libanotica, B. aristata, Rhizoma Coptidis, Rhizoma Coptis*188Neferine*Nelumbo nucifera, Plumula nelumbinis*141Fangchinoline*Stephania tetrandra*115[@bib0080]Dauricine*Menispermum dauricum*110[@bib0071]Other BBIQs352[@bib0127]antioquine, aromoline, baluchistine, berbacolorflammine, berbibuxine, calafatimine, cocsoline, cocsulinine, colorflammine, curacautine, curine, cycleahomine, cycleanine, cycleatjehine, daphnine, daphnoline, daurisoline, dihydrosecocepharanthine, dihydrothalictrinine, faralaotrine, funiferine, gilletine, hernandezine, johnsonine, krukovine, liensinine, limacine, limacusine, macolidine, macoline, malekulatine, norpanurensine, obaberine, oblongamine, osornine, oxandrine, phaeantharine, racemosidine, repandine, sinomenine, temuconine, thalbadenzine, thalfine, thalibrunine, thalictine, thalictrinine, thalidasine, thalidezine, thalmethine, thalmine,, tiliageine, tubocurine[^1]

Optimized methods for the analysis of these alkaloids in *S. cephalantha* extracts have been reported ([@bib0135], [@bib0067], [@bib0130]), as well as green extraction technologies (using ethanol--water mixtures) to purify CEP from *S. rotunda* tuber ([@bib0018]). The content of CEP in *S. cephalantha* is 2.9% ([@bib0118]). The natural product, extracted from the plant, is used for medicinal applications. The total synthesis of CEP, first reported in 1967 ([@bib0117], [@bib0118]), is not cost-effective. It should be noted that recently, the absolute configuration of CEP has been reassigned from (1R,1′S) to (1R,1′R) using quantum theory ([@bib0097]). The pharmaceutically used form of CEP is a dihydrochloride salt. There are several patents specific to CEP, such as (i) a US patent describing the extraction and purification of CEP from rhizomes of *S. sasakii* Hayata published in 1941; (ii) an European patent application covering the preparation of anti-HIV composition containing CEP in 1992; (iii) A Japanese patent about the preparation CEP for the treatment and prevention of intestinal diseases in 1996; (iv) A Chinese patent describing the method of preparation of CEP hydrochloride filed in 2012; (v) a US patent disclosing the pharmaceutical preparation of CEP and tetrandrine salts and (vi) the production of CEP at the scale of 5--10 kg under good manufacturing practice conditions mentioned in a recent US patent.

CEP was discovered in 1934 and then rapidly tested in Human, based on the traditional use of the medicinal plant. A paper published in 1949 mentions that in 1937 CEP, given in tablets or in liquid, contributed to reduce considerably (from 41% to 22%) the average mortality in patients with severe pulmonary tuberculosis at the Yokohama Sanatorium in Japan ([@bib0035]). At that time, the antitubercular activity of CEP was largely promoted, but later the drug was abandoned, superseded by more active products ([@bib0002]). Nevertheless, the initial successful clinical use of CEP for the treatment of tuberculosis has encouraged its use in other pathological indications (*e.g.*, pertussis, leprosy and lupus vulgaris) and associated research activities to elucidate its mode of action. The biochemical and biological properties, and clinical applications of CEP are reviewed below.

Anti-oxidative properties -- free radicals scavenging {#sec0003}
=====================================================

Reactive oxygen radicals (ROS), generated metabolically or induced by radiations or chemicals, can engender cell damages, in particular, lesions of nucleic acids. Accumulated DNA damages can be deleterious and toxic to cells, via DNA strand breaks and/or the accumulation of mutations and other types of molecular rearrangements. CEP can protect nuclear DNA from the damages induced by endogenous oxidants, most likely via its antioxidant properties ([@bib0031]). The scavenging properties of CEP also provide a protection of DNA from the radicals generated endogenously during oxidative metabolism. The drug can also reduce the generation of radicals through activation of NADH oxidase ([@bib0078]). CEP has effective ferrous ion (Fe^2+^) chelating capacity, similar to EDTA for example. The anti-lipid peroxidation activity of CEP is also due to its direct radical scavenging activity ([@bib0056]). One of the two amine moieties in the CEP molecule is responsible for the radical scavenging activity ([@bib0055]). Many BBIQ alkaloids show antioxidant activities.

Anti-inflammatory properties - NFκB inhibition {#sec0004}
==============================================

The anti-inflammatory effects of CEP are in large part at the origin of the extensive use of *S. cephalantha* extracts in folk medicine for the treatment of rheumatism, lumbago, nephritis edema, dysentery and other inflammatory diseases. The capacity of CEP to reduce the production of oxidants leads subsequently to the mitigation of the transcription factor NFκB which is a potent regulator of inflammatory molecules. CEP reduces NFκB expression. The anti-inflammatory potential of CEP can be useful in a variety of pathological situations. For example, the capacity of CEP to inhibit inflammation and oxidation leads to protective effect against muscle and kidney injuries induced by limb ischemia/reperfusion ([@bib0011]). CEP was also found to ameliorate diabetic nephropathy in a rat model, through inhibition of NFκB and decreased levels of IL-1β and TNF-α ([@bib0100]). The drug mitigates pro-inflammatory cytokine response in lung injury induced by hemorrhagic shock/resuscitation in rats ([@bib0052]). The release of the pro- inflammatory cytokines TNF-α, IL-1β and IL-6 was found to be reduced after treatment with CEP in cell and mouse models of LPS-induced inflammation and the protective effects occur, at least in part, via NFκB inhibition. Indeed, in a mouse model of lipopolysaccharide (LPS)-induced mastitis, CEP inhibited the phosphorylation of NFκB p65 subunit and the degradation of its inhibitor IκBα ([@bib0021]), thereby inhibiting the translocation of NFκB from cytosol to nucleus ([@bib0094]). However, recently CEP was found to prevent the phosphorylation of JAK2 and STAT1, but did not interfere with the NFκB pathway ([@bib0004]). In this cell model, CEP inhibited the production of the chemokine CXCL10 induced by IFN-γ, via inhibition of the JAK2/STAT1 signaling pathway ([@bib0073]). Inhibition of NFκB is a mechanism common to several BBIQs. In particular, tetrandrine was shown to inhibit IκBα and NFκB p65 phosphorylation and this effect account, at least in part, for its anti- inflammatory properties ([@bib0027], [@bib0131]). Berbamine, another BBIQ, also exerts anti-inflammatory effects via inhibition of NFκB and MAPK signaling ([@bib0047]). Neferine also inhibits the activation of the NFκB signaling pathway and prevents its nuclear translocation ([@bib0070]).

Inhibition of drug efflux transporters {#sec0005}
======================================

The overexpression of drug transporters on the membrane of cancer cells is a major cause of multi-drug resistance to cancer chemotherapy. Among the many transporters, ABCC10 (also known as MRP7) can be inhibited by a variety of drugs including certain kinase inhibitors (lapatinib, erlotinib, imatinib) and different natural products such as CEP. This natural product can reverse completely the resistance to paclitaxel of cells expressing ABCC10, increasing the intracellular accumulation of the anticancer agent and inhibiting its efflux ([@bib0140]). The synergy between CEP and paclitaxel has led to the design of co-loaded polymeric nanoparticules that proved active against gastric cancer models *in vitro* and *in vivo* ([@bib0134]). ABCC10 is a broad-specificity transporter of xenobiotics, including many antitumor drugs (taxanes, epothilone B, vinca alkaloids, cytarabine, tamoxifen). Therefore, CEP can promote the anticancer activity of most of these compounds. But CEP can also interfere with other transporters, in particular ABCB1 (also known as MDR1 or P-gp) and ABCC1 (MRP1). CEP can be used to reverse resistance to many cytotoxic agents and thus to sensitize tumors to certain chemotherapeutic substances ([@bib0053]). It potently enhances the sensitivity to cytotoxic agents such as doxorubicin in K562 leukemia cells, not only via a reversal of ABCB1-mediated multi-drug resistance (MDR) but also increasing the accumulation of doxorubicin in nuclei ([@bib0043]). The suppression of ABCB1 function by CEP would derive from an inhibition of the PI3K/Akt signaling pathway. Inhibition of PI3K/Akt pathway by CEP leads to a down-regulation of ABCB1 expression and then MDR-reversion in ovarian cancer cells ([@bib0042]). But a direct interaction of CEP with specific drug transporters at the plasma membrane or via an indirect lipid-mediated effect cannot be excluded. For example, the related BBIQ neferine is believed to bind directly to ABCB1 ([@bib0049]).

Binding to proteins: Hsp90 and others {#sec0006}
=====================================

The heat shock protein 90 kDa (Hsp90) has attracted significant interest as a viable drug target, particularly for cancer. Inhibitors targeting the ATPase domain of Hsp90 demonstrate potent anti-proliferative effects, but have failed clinical trials due to associated toxicities. Interestingly, it has been reported that CEP interacts with the middle domain of Hsp90α more strongly than the 3 other biscoclaurine alkaloids berbamine, isotetrandrine and cycleanine ([@bib0030]). The interaction of CEP with Hsp90 and other molecular chaperone proteins, deserves further studies. CEP also inhibited another ATPase, namely Na(+),K(+)-ATPase, although in this case the inhibition by CEP is much less potent than inhibition by cycleanine ([@bib0102]).

Interaction with cell membranes {#sec0007}
===============================

Early Japanese studies pointed out that CEP is a membrane-interacting and -stabilizing agent ([@bib0107]). The drug reduces the plasma membrane fluidity suggesting a direct interaction with the lipid bilayer. The amphipathic character of CEP facilitates its interaction with cell membranes, increasing permeability and interaction with lipophilic compounds. The membrane effects would be at the origin of the inhibition of snake venom-induced hemolysis by CEP ([@bib0081]) and the drug-induced enhancement of fatty acid synthesis in rat white adipocytes ([@bib0088]). The drug does not directly act on the insulin-involved glucose metabolism but by changing the cell membrane condition, it modifies the cell response to insulin ([@bib0088]). The membrane effects of CEP might also be implicated in the capacity of the drug to enhance the thermosensitivity of cancer cells, acting as a mild thermosensitizer ([@bib0132]). The membrane stabilization effect of CEP is a prime element of its mode of action. Intracellular membranes are also affected. CEP can inhibit the endolysosomal trafficking of free-cholesterol and low-density lipoproteins, leading to the dissociation of mTOR from lysosomes and inhibition of its downstream signaling. This effect may directly contribute to the drug-induced inhibition of angiogenesis and tumor growth ([@bib0074]).

Binding to G-quadruplex nucleic acid structures {#sec0008}
===============================================

Two independent studies have reported that CEP can bind and stabilize G-quadruplex formed by G- rich sequences in DNA and RNA. G-quadruplex DNA are DNA secondary structures formed from planar stacks of guanine tetrads stabilized by Hoogsteen hydrogen bonding. Certain small molecules have the capacity to stabilize these structures. CEP was found to stabilize a G-quadruplex DNA existing in the 3′-flanking region of the STAT3 gene, thereby decreasing the expression of STAT3 in cultured cardiomyocytes ([@bib0063]). G-quadruplexes also exist in RNA, in particular telomeric RNA to regulate telomerase activity. CEP was found to bind tightly to two types of G-quadruplex telomeric RNA sequences, with an affinity higher than that of its analogs fangchinoline and tetandrine ([@bib0015]). This G-quadruplex stabilization property may contribute to the anticancer activity of CEP.

Vasodilatation effect {#sec0009}
=====================

The cutaneous microcirculatory effects of CEP have been investigated. The drug induces notable and transient vasodilatation with vasomotion. Vasodilation and improvement of peripheral circulation was also noted in early study suggesting a beneficial use to treat sickle-cell patients ([@bib0089]). The vasodilatator effects of CEP improved cutaneous microcirculation in a rabbit model ([@bib0003]). This effect on the microcirculation, coupled with the potent anti-inflammatory activity, speak for the use of CEP to treat certain dermatological and orofacial inflammatory lesions, such as oral lichen planus ([@bib0082]). In early studies, the vasodilatator effects of CEP was also evidenced using isolated vessels from rats and CEP proved more efficient than its analogs isotetrandrine and berbamine ([@bib0050]). Similarly, the related BBIQ alkaloid curine has been described as a vasodilator ([@bib0079]).

Anti-proliferative activities -- induction of tumor cell death {#sec0010}
==============================================================

CEP inhibits the proliferation of different cell types *in vitro,* including many cancer cell lines, T-cell lines and peripheral mononuclear cells (PBMC). The IC50s are usually in the 1--10 μM range and the drug is non-mutagenic. CEP can trigger apoptosis, via the activation of caspases and DNA fragmentation. The drug affects the cell cycle, generally arresting cells in the G1 and S phases. A mechanistic study using hepatocellular carcinoma HuH-7 cells revealed that CEP induces chromatin condensation and nuclear fragmentation, likely resulting from an oxidative stress and activation of stress activated kinase JNK1/2, MAPK p38 and ERK ([@bib0010]). Induction of apoptosis by CEP has been observed in many cell types: dendritic cells ([@bib0124]), primary effusion lymphoma ([@bib0111]), leukemia cells ([@bib0128]), melanoma cells ([@bib0144]), cholangiocarcinoma ([@bib0105]), ovarian cancer cells ([@bib0095]), myeloma cells ([@bib0054]), osteosarcoma cells ([@bib0013]) and breast cancer cells ([@bib0028]). In colorectal cancer cells, cell cycle arrest and apoptosis may be mediated through up-regulation of p21Waf1/Cip1, down-regulation of cyclin A and Bcl-2 and induction of ROS production ([@bib0096]). In fact, the mechanism of apoptosis caused by CEP is complex, likely cell-type dependent, and plurimodal. A direct interaction with mitochondria in cells has been reported, inhibiting Ca^2+^-induced swelling, depolarization, cytochrome *c* and Ca^2+^ releases ([@bib0085]). CEP-induced mitochondrial dysfunctions were noted in several cancer cell types ([@bib0041]).

Both drug-induced apoptosis and autophagy were noted in breast cancer cells, possibly linked to perturbation of the AKT/mTOR signaling pathway ([@bib0028]). Law and coworkers reported that CEP induces autophagic cell death via an activation of the AMPK kinase activity ([@bib0059]). The biscoclaurine hernandezine, which is structurally close to CEP, can trigger cell death via an activation of the AMPK-mTOR signaling cascade and its cytotoxic action is independent of apoptosis ([@bib0060]). Similar data were reported with CEP, and this capacity to enhance autophagy likely contributes to its anticancer activity ([@bib0059]). This is significant considering that most chemotherapy-resistant cancers have defective apoptotic pathways. The direct activation of AMPK by CEP mays be beneficial not only to trigger cancer cell death but also in other pathologies, in particular metabolic disorders, considering the implication of AMPK in glucose and lipid metabolisms. AMPK activation is a key property of CEP and related biscoclaurine alkaloids.

There are numerous anticancer *in vitro* studies with CEP but fewer studies *in vivo*. Interestingly, a modest but significant antitumor activity has been reported in a xenograft model of SaOS2 osteosarcoma cells. Treatment of tumor-bearing mice with CEP at 20 mg/kg/day for 20 days led to a reduction of tumor volume and a diminished expression of STAT3 in the residual tumor ([@bib0013]). A significant inhibition of tumor growth and infiltration was also observed after CEP treatment of immunodeficient mice inoculated with a primary effusion lymphoma. The antitumor activity would result from the capacity of CEP to abrogate the NFκB activity by blocking phosphorylation of p65 subunit, inhibiting thus nuclear translocation of NFκB and its binding to DNA ([@bib0111], [@bib0105]). In a xenograft model of choroidal melanoma, CEP (25 mg/kg, 5 times/week for 4 weeks) reduced tumor growth and the effect was associated with an activation (phosphorylation) of JNK1/2 ([@bib0144]).

Inhibition of cell migration -- anti-metastatic and anti-atherosclerosis properties {#sec0011}
===================================================================================

Migration and proliferation are common characteristics of cancer cells and vascular smooth muscle cells (VSMC). In both situations, CEP has been shown to inhibit the motility of the cells and their growth. The anti-migratory effect of CEP on VSMCs is due to its inhibitory effect on matrix metalloproteinase (MMP)-9 expression, preventing the degradation of extracellular matrix components. This effect, coupled with attenuation of inflammation and lipid peroxidation, confers to CEP anti-atherosclerosis properties ([@bib0094]). A CEP-induced suppression of MMP-9 production was also observed in human salivary gland acinar cells, via a down-regulation of NFκB ([@bib0005]). The inhibition of MMP-9 by CEP prevents the destruction of the acinar structure in the salivary glands of patients with Sjögren\'s syndrome ([@bib0006]). Similar properties are invoked to account for the anti-metastatic effects of CEP. The drug suppresses the metastatic potential of cholangiocarcinoma cells by reducing cell motility and invasion, via a mechanism potentially involving suppression of adhesion molecules (ICAM-1) and matrix metalloproteinase (MMP)-2 ([@bib0122]). Other biscoclaurine alkaloids structurally close to CEP, such as fangchinoline ([@bib0014]) and tetrandrine ([@bib0139]) were found to exhibit anti-metastatic effects as well. Interestingly, the anti-metastatic activity of fangchinoline in human gastric cancer cells was also found to implicate the suppression of MMP-2 and MMP-9, increase of TIMP1 and TIMP2 genes, and inhibition of AKT phosphorylation ([@bib0014]). Fangchinoline inhibits metastasis and migration of melanoma and glioma cells *in vitro*, as well as it suppresses in a dose-dependent manner the adhesion, migration, and invasion human gastric cancer cells ([@bib0080]). Tetrandrine inhibits hepatocellular carcinoma cell invasion and migration by repressing the autophagy-dependent Wnt/β-catenin and metastatic tumor antigen 1 (MTA1) signaling pathways ([@bib0139]).

Inhibition of angiogenesis {#sec0012}
==========================

The formation of tubule networks of human umbilical vein endothelial cells (HUVEC) and human dermal microvascular endothelial cells (HMVEC) is a classical *in vitro* model to evaluate the anti-angiogenic effects of drugs. CEP inhibits VEGF-promoted tubule formation in HUVECs, an effect that is likely associated with the inhibition of VEGF and IL-8 expression involved in the blockade of NFκB activity ([@bib0032]). CEP was also found to inhibit angiogenesis in HUVEC and in zebrafish in a cholesterol-dependent manner, as mentioned above ([@bib0074]).

Anti-cancer activity of CEP in drug combinations {#sec0013}
================================================

Owing to its capacity to modulate drug transporters such as PgP and MRP7, CEP can be combined with various drugs. Synergistic effects have been observed with different anticancer drugs, such as the tetramethylnaphthalene anti-viral derivative TMNAA ([@bib0119]), the nitrosourea nimustine ([@bib0057]), the anthracycline doxorubicin ([@bib0086]), the taxanes paclitaxel and docetaxel ([@bib0075]), the recently approved new pan-EGFR inhibitor dacomitinib ([@bib0115]), and other anticancer agents ([@bib0046]). CEP enhances the antitumor activity of cisplatin in lung and breast cancer xenografts in mice ([@bib0083]). Its capacity to downregulate the mRNA expression of MDR1 and P-gp, through activation of c-Jun and enhancement of p21 expression, leads to an increase sensitivity of the tumor to cisplatin treatment ([@bib0142]). Interestingly, CEP not only promotes the anticancer activity of cisplatin, via an inhibition of P-gp but it can also reduce its renal toxicity through an induced expression of metallothionein ([@bib0108]). In K562/MDR leukemia cells, CEP was found to be very effective for the reversal of the resistance to imatinib ([@bib0083]). Recently, it was shown that the combination of CEP and 5-fluorouracil additively induced apoptotic and necrotic cell death, via an upregulation of the expression of BAK and cleaved PARP in HT-29 human colorectal cancer cells harboring mutant p53, both *in vitro* and *in vivo* ([@bib0121]). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) functions as a selective apoptosis-inducing ligand in cancer cells with normal cells remaining unaffected. CEP enhances TRAIL-mediated apoptosis through a down-regulation of survivin expression, not by direct inhibition of survivin mRNA expression but via a downregulation of a deubiquitin protein that modulates survivin expression in renal carcinoma cells ([@bib0106]).

Radiosensitization {#sec0014}
==================

Radiotherapy is often used for the treatment of oral squamous carcinoma, the most common epithelial malignancy in the oral cavity, frequently observed in patients who smoke and drink heavily. CEP was found to improve the response to radiotherapy in oral squamous carcinoma cell lines. The drug exhibited a strong inhibitory effect on DNA double-strand break repair after radiation and the combined therapy markedly increased tumor cell apoptosis. The combination of CEP plus radiation caused growth inhibition and tumor regression of tumors in mice ([@bib0033]). CEP inhibits the production of irradiation-induced IL-6 and IL-8, which are downstream targets of NFκB ([@bib0113]). A similar radiation sensitization by CEP was also reported using the human cervical adenocarcinoma HeLa cell line. In this case, CEP efficiently decreased ionizing radiation-induced STAT3 and COX-2 activation. *In vivo* administration of CEP combined with radiation in HeLa xenografts enhanced tumor growth delay and apoptosis, with reduced expression of STAT3, Bcl-2, c-Myc, and COX-2 ([@bib0022]).

Treatment of radiation-induced leukopenia and thrombocytopenia {#sec0015}
==============================================================

Administration of CEP to accelerate the recovery from leukopenia after X-ray irradiation (or mitomycin treatment) in cancer therapy is one of the classical and well-established use of the alkaloid. The beneficial effect of CEP on leukopenia was first noted in 1965 and then firmly demonstrated in the early 1980s ([@bib0093]). The drug can be used to treat but also to prevent from leukopenia, especially neutropenia, in patients treated with anticancer drugs. A large multi-center clinical study demonstrated that CEP is safe and significantly effective for the management of leukopenia caused by radiotherapy, protecting leukocytes from the damaging effects of radiations and showing no effect on erythrocyte and platelet counts, according to this retrospective study ([@bib0051]). However, other studies indicated that CEP has the capacity not only to limit the platelet destruction process but also to facilitate the platelet production process, via a drug-induced increase of the number of colony-forming unit of megakaryocytes ([@bib0101]). Thus, CEP may prolong the platelet lifespan.

Immuno-modulation -- treatment of sepsis, chronic immune thrombocytopenia {#sec0016}
=========================================================================

CEP therapy, alone or in combination with prednisolone, improves symptoms of chronic immune thrombocytopenia ([@bib0112]). The drug was found to be effective in halting the progression of immune thrombocytopenic purpura in a patient with multiple myeloma ([@bib0110]). A link can be established between the capacity of CEP to inhibit the platelet activation and its capacity to alter phospholipid dynamics and functions. This is coherent with early studies showing that inhibition of platelet aggregation by CEP is accomplished during the early, membrane-related activation process. A recent study conducted in a pediatric population also underlined the useful effect of CEP for the management of chronic immune thrombocytopenia ([@bib0133]).

CEP can reduce the production of IL-6 and TNF-α in LPS-stimulated dendritic cells ([@bib0123]). The potent anti-inflammatory activity of CEP speaks for the potential use of the drug for treating systemic inflammatory response syndromes such as sepsis. Along these lines, CEP was found to attenuate acute lung injury and septic shock after smoke inhalation in sheep ([@bib0084]). Treatment with CEP was also found to delay lethal shock induced by an infection with a mutant of *Salmonella typhimurium* ([@bib0076]). A later study revealed that CEP could have a preventive effect on the lethal action of endotoxin or TNFα-induced lethal shock, through a suppression of nitric oxide production in macrophages ([@bib0099]). As a potent immunoregulatory agent, CEP may have a strong potential against various autoimmune diseases and allergy.

Inhibition of bone resorption {#sec0017}
=============================

CEP has been shown to inhibit osteoclast formation in a model of estrogen deficiency-induced osteoporosis *in vivo*, without affecting bone formation. Apparently, the attenuation of osteoclastogenesis results from the impairment of the JNK and PI3K-AKT signaling pathways ([@bib0143]). CEP inhibits the phosphorylation of JNK (a member of the MAPK family) and suppresses RANKL-induced phosphorylation of PI3K and AKT, thereby impairing osteoclastogenesis. In another recent study, CEP was also found to inhibit the expression of several osteoclast-differentiation marker genes and to inhibit RANKL-induced osteoclast formation ([@bib0065]). These two recent works suggest that CEP might be useful to prevent osteoporosis. Tetrandrine was also shown to attenuate bone erosion in a model of collagen-induced arthritis ([@bib0048]).

Antiviral properties {#sec0018}
====================

The capacity of CEP to suppress the production of inflammatory cytokines and chemokines in cells is at the origin of its antiviral activity. The anti-HIV activity of CEP was first mentioned in a patent application from 1991. The drug can inhibit HIV-1 replication in latently infected U1 cells, through inhibition of NFκB which is a potent inducer of HIV-1 gene expression. It is a highly potent inhibitor of HIV-1 replication in chronically infected monocytic cells ([@bib0090]). This property, coupled with its capacity to cross the blood-brain barrier and induce neural cell death, make CEP a potential agent against HIV-1 encephalopathy ([@bib0091]). The anti-HIV-1 activity not only relies on NFκB inhibition but also CEP-induced inhibition of the HIV-1 entry process by reducing plasma membrane fluidity ([@bib0077]). Synthetic derivatives of CEP endowed with more potent anti-HIV-1 activities have been described. Replacement of the 12-O-methyl group of CEP with a 12-O-ethylpiperazinyl substituent reinforces the activity against HIV-1 replication ([@bib0007]). The drug can also affect the replication of other viruses, in particular it was found to be active against both wild-type and lamivudine-resistant clinical isolates of the hepatitis B virus ([@bib0141]) and early studies demonstrated an activity against Herpes zoster. CEP exhibits strong anti-HSV1 activity ([@bib0066]) and proved active against human T-lymphotropic virus type 1 (HTLV-1)-infected T-cell lines when combined with the tetramethylnaphthalene derivative TMNAA ([@bib0119]). Finally, an activity against severe acute respiratory syndrome (SARS)-related coronaviruses has been also reported ([@bib0137]).

Interestingly, molecular docking simulations predicted that CEP could bind to protein targets of the Ebola virus ([@bib0125]). The US company Texas Biomed is developing a more bioavailable, or more easily absorbed, formulation of CEP, which might be combined with chloroquine to combat the Ebola virus.

Treatment of alopecia {#sec0019}
=====================

CEP is used for the treatment of alopecia areata, also known as spot baldness, an autoimmune disorder which can be treated with topical corticosteroids and/or minoxidil ([@bib0039]). The first publications describing the therapy of alopecia with CEP date from 1956 in French and 1969 in Japanese ([Fig. 3](#fig0003){ref-type="fig"}). The anti-alopecia activity of CEP was promoted already in the mid-1950s and remains largely cited today. But over the past 50 years, very limited scientific evidences have been published to confirm and demonstrate the efficacy of CEP to treat alopecia. CEP can protect against aminoglycoside-induced hair cell death ([@bib0092]) and it can stimulate cell proliferation and delayed initiation of differentiation and keratinization of the cultured murine cells the hair apparatus ([@bib0116]). It can also promote the proliferation of cultured hair cells from the murine skin ([@bib0087]). The capacity of CEP to stimulate hair growth may result from the drug-induced production of IGF-1 which is an anagen-prolonging growth factor, in dermal papilla cells ([@bib0044]). A more recent study describing the use of topical lipoid CEP (a lotion at 0.1% CEP) showed only a minor (and not statistically significant) effect on the density, growth rate and thickness of hairs ([@bib0045]). Clearly, the use of CEP for the treatment of alopecia areata is not supported by sufficient pharmacological and clinical evidence. However, the drug or an extract of *S. cephalantha* can be found in different non-medical topical lotions commercialized in Japan.

Treatment of snake bites {#sec0020}
========================

This is another historical use of CEP: the treatment of mamushi bites, a specific pit viper (*Gloydius blomhoffii*) found throughout Japan. It is also seen in China and Korea. Mamushi bites cause severe swelling (causing compression of peripheral arteries and/or compartment syndrome of the extremities) and pain that spreads gradually from the bite site. In general, the platelet count gradually decreases due to the platelet aggregation activity of the venom. Both antiserum and CEP are widely used for the treatment of mamushi snakebites. After the bite, the rapid use of an antivenom is essential to neutralize both the hemorrhagic and lethal activities of the venom. CEP has been proposed as a possible alternative therapy to antivenom, to lessen the inflammation and the pain caused by the snake bite ([@bib0037]). In the severe cases of bites, the antivenom is the major treatment recommended. The use of CEP alone is not recommended as it cannot neutralize the circulating venom ([@bib0038]). In 2000, Abe and coworkers showed that CEP inhibits two species of phospholipase B (α and β) purified from the venom of the giant hornet (*Vespa mandarinia*) ([@bib0001]).

Antiparasitic activities {#sec0021}
========================

CEP has been shown to be a trypanothione reductase inhibitor ([@bib0024]), an enzyme considered as a robust target to find drugs against Leishmaniasis and the Chagas disease. But the antiparasitic activity of CEP is very limited ([@bib0025]). However, CEP potently enhances the sensitivity of the malaria pathogen *Plasmodium falciparum* to chloroquine ([@bib0034]). CEP has a modest direct inhibitory effect on the trophozoite stage of parasite growth, but acts as a modulator of resistance, capable of prolonging the clinical utility of chloroquine ([@bib0114]). The cepharanthine-chloroquine association is synergistic ([@bib0012]). The combination of CEP with chloroquine (or amodiaquine) improved significantly the survival of mice and extended the delay for parasitic recrudescence ([@bib0019]). CEP blocks P. falciparum development in ring stage, affecting multiple metabolic pathways, such as cell-cell interactions, glycolysis and isoprenoid pathways ([@bib0020]). These data are consistent with the use of *Stephania* extracts in traditional medicine for the treatment of malaria-related fever.

Other activities {#sec0022}
================

Other types of bioactivity have been attributed to CEP, linked to its anti-inflammatory and anti-oxidant properties. Notably, a potent anti-atherosclerotic effect through attenuation of inflammation, lipid peroxidation and vascular smooth muscle cell migration and proliferation, has been described ([@bib0094]). Similarly, CEP might be useful to halt the progression of diabetic nephropathy, caused by an elevation of oxidative stress and proinflammatory cytokines in situations of hyperglycemia ([@bib0100]). CEP was also found to selectively inhibit the binding of amyloid-β oligomers to Ephrin type-B receptor 2 (EphB2) and A-β oligomers are believed to be key molecules involved in the pathogenesis of Alzheimer\'s disease ([@bib0109]). NFκB is also considered a promising target for inflammation-based Alzheimer\'s disease therapy and many phytochemicals able to interfere with the NFκB pathway are considered for the treatment of this most prevalent form of dementia ([@bib0104]).

CEP might also be useful to treat human autoimmune thyroid diseases, via its capacity to block T-cell activation by thyroglobulin peptides ([@bib0062]). In this later case, CEP was first identified using a virtual in silico screening procedure from a library of approved drugs and its capacity to inhibit peptide binding to a HLA-DR variant protein and to block T-cells activation *in vitro* and *in vivo* were confirmed experimentally ([@bib0062]). This discovery opens a new clinical field to explore the use of CEP for the treatment of different autoimmune disorders such as arthritis or Sjögren\'s syndrome. And last, more exotically, CEP was tested as an antifouling compound for marine paints but was found to be less active than other alkaloids such as camptothecin ([@bib0023]).

CEP has probably other unanticipated targets and properties. In particular, an action on certain ion channels may be envisioned considering the activity of related products. Recently, tetrandrine was found to be a potent and selective inhibitor of the Ether-à-go-go-1 (Eag1) ion channel that plays important roles in tumor proliferation, malignant transformation, invasion and metastasis ([@bib0126]). However, the structural analogy between the two BBIQ is not sufficient to suspect an activity. For example, the BBIQs berbamine and fangchinoline were found to bind to the water transporting protein aquaporin-4 expressed in the CNS whereas CEP and cycleanine were found to be inactive ([@bib0120]).

Discussion and perspective {#sec0023}
==========================

CEP is a well-established alkaloid, known for 85 years and the only cyclic BBIQ used in the clinic to treat Human diseases. But surprisingly it has not been extensively studied. For example, a search through of the PubMed database gave 331 references for CEP *vs.* 910 for the related BBIQ tetrandrine which is not used clinically ([Table 1](#tbl0001){ref-type="table"}). As presented here, CEP was discovered in 1934, launched in Japan in 1951 and remains used in the clinic today for the treatment of a variety of diseases and symptoms ([Fig. 3](#fig0003){ref-type="fig"}). It was initially considered as a promising drug for the treatment of tuberculosis, but today the alkaloid is principally used for its anti-inflammatory, immuno-modulatory properties, notably for the treatment of anemia, alopecia and snake bites. The drug can be administered in large dose and over a long term, either orally or intravenously. It is important to underline that this plant natural product is safe, well tolerated, inducing very limited undesirable effects. Side effects are said to be insignificant and rarely appearing.

Today CEP remains almost exclusively prescribed in Japan (99% Japan, 1% South Korea), principally in the form of 1 mg tablets orally administered, although the bioavailability of CEP by the oral route is limited ([@bib0016]). Each tablet (100 mg) contains 1% CEP mixed with lactose, talc, calcium stearate, magnesium stearate etc. (mainly from KAKEN SHOYAKU, Japan). The usual oral dosage for the treatment of alopecia areata in adults is 1.5--2 mg CEP per day divided in 2--3 doses taken after meals. The dosage is generally higher (3--6 mg/day) for the treatment of leukopenia and usually 1 mg/day for the treatment of bronchial asthma. There is also a liquid form, corresponding to 1 ml or 2 ml vials with 0.5% CEP in a fluid solution (2% benzyl alcohol, 1% NaCl and HCl acid) for injection, but this form is more rarely used. Over the past five years, the pharmaceutical sales of CEP-containing products remained relatively stable, with a slight increase of the volume of products (+8% from 2014 to 2018) but a decrease of the associated economic impact (−14% over the same 5-years period), as illustrated in [Fig. 5](#fig0005){ref-type="fig"} . CEP is an inexpensive drug. The sale volumes are limited, corresponding to a very niche and national market. But the drug is well introduced in Japan, being authorized for 68 years now.Fig. 5Pharmaceutical sales of CEP for years 2014--18 (from IMS Health, now IQVIA). The graph shows both the annual sales in k€ (left axis) and in k-units (right axis). Numbers for year 2018 are estimates based on the June 2018 MTA (Moving Annual Total) data.Fig 5

In 2011 Rogosnitzky and Danks concluded that CEP is a fascinating agent with a complex set of physiological actions and an array of clinical benefits ([@bib0098]). Eight years later, the same conclusion can be reinforced. New properties have been discovered, such as the capacity of CEP to bind to quadruplex nucleic acids and to inhibit of bone resorption. It is difficult to summarize its multimodal mechanism of actions but a tentative scheme can be delineated ([Fig. 6](#fig0006){ref-type="fig"} ). The mode of action is complex, implicating effects at the plasma membrane (inhibition of drug efflux pumps, membrane rigidification), nuclear effects (G4 stabilization; modulation of gene expression) and cytoplasmic activities, in particular a regulation of the AMPK and NFκβ signaling pathways. With no doubt, the AMPK-NFκβ axis is central to the mode of action of CEP. Accumulating evidence from studies with various drug types indicate that AMPK activation promotes anti-inflammatory responses in cells exposed to stress/danger signals mainly through inhibition of NFκB signaling. There are many examples showing that activation of AMPK is linked to inhibition of NFκB and suppression of the downstream biological effects, such as autophagy activation ([@bib0136]). Moreover, AMPK exerts also a protective role on the antioxidant defense system. Therefore, AMPK activation by CEP can also contribute to the antioxidant effects. Several studies promote the development of AMPK-targeted therapeutics to treat inflammation and related diseases. In this context, the use of CEP as an AMPK activator/NFκB inhibitor should be encouraged. It is worth noting also that the AMPK-NFκβ axis has been invoked to explain the bioactivity of other BBIQs, in particular the anti-inflammatory activity of neferine ([@bib0029]) and the induction of apoptosis by isolensinine ([@bib0138]). AMPK, the so-called "cellular energy regulator", might well be the pivotal regulator of CEP bioactivity. But it some cases, the Ras/Erk signaling axis seems to be predominantly implicated, notably to regulate cells growth. Interestingly, the related BBIQ krukovine also represses the growth and proliferation of cancer cells by inactivating AKT signaling pathway and downregulating the RAF-ERK signaling pathway ([@bib0058]).Fig. 6Main signaling pathways and sites of action of CEP in cells. The multifaceted mechanism of action of CEP leads to several clinical applications (treatment of snake bites, alopecia aerata, xerostomia, leukopenia). Other potential applications of CEP are also explored for the treatment of cancer, osteoporosis, virus and parasites infections, sepsis and chronic inflammatory diseases.Fig 6

More generally, CEP can be qualified as a protector and a promotor. The drug protects cells, from lipid oxidation, from oxidative DNA damages, from pro-inflammatory cytokines production. At the same time, it promotes the activity of combined drugs and radiations for the treatment of cancer and malaria for examples. One third of the publications on CEP refers to cancer, through the study of drug- induced cell death (apoptosis, autophagy) and drug combinations. But these are mechanistic studies essentially; it is unlikely that the drug can be repositioned in cancer therapy. However, it can open the door to the use and development of other BBIQ, such as tetrandrine from *Stephania tetrandra* Radix which is perhaps a more promising anticancer agent than CEP ([@bib0068], [@bib0009]). CEP itself could be used more largely for the treatment of cancer-related conditions such as xerostomia, anemia or leukopenia.

New horizons for CEP have been evoked in this review, such as a repositioning for the treatment of bone disorders in particular osteoporosis. It really makes sense because NFκB is a robust therapeutic target in inflammatory-associated bone diseases ([@bib0064]). CEP activates AMPK by targeting NFκB to suppress autophagy. As such, the drug could also be considered to prevent the development of pulmonary arterial hypertension ([@bib0136]). Other therapeutic perspectives can be proposed. As a well-tolerated, orally available inhibitor of NFκB-mediated inflammation, CEP certainly merits further investigation for efficacy in clinical trials for disorders characterized by inflammation and membrane injury molecular pathways. In particular, CEP might be considered for the treatment of Duchenne muscular dystrophy (DMD) which is a neuromuscular disorder causing progressive muscle degeneration. In DMD, NFκB is activated and drives inflammation and muscle degeneration while inhibiting muscle regeneration. The absence of dystrophin makes skeletal muscle more susceptible to injury, resulting in breaches of the plasma membrane and chronic inflammation in DMD. Novel NFκB inhibitors are currently evaluated as new treatments for DMD patients. It would also make sense to evaluate the potential of CEP in this indication, and in other chronic inflammatory diseases. Along the same vein, CEP might be useful to limit the progression of osteoarthritis, a chronic degenerative joint disease incredibly prevalent in older age. CEP would not repair the already degraded cartilage, but the drug might avoid damage extension to the surrounding tissue, by limiting the production of pro-inflammatory cytokines and chemokines ([@bib0036]). In particular, osteoarthritis patients suffering from a cancer and treated with a regulator of the PD1/PDL1 immune checkpoint might face an aggravation of their osteoarthritis due to a treatment-induced elevated expression of inflammatory cytokine in macrophages ([@bib0072]). The use of CEP might thus be useful to limit osteoarthritis progression. A new life for an old drug? Maybe. CEP is not a « one pill fits all » medication but certainly an under-explored drug which should be reconsidered. Hopefully this review will contribute to the renaissance of this well-established alkaloid.
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